Nimodipine SG 2003.

Methods	Please see details below.
Participants	1750 women with PE, planned delivery and no previous MgSO4. BP ≥140/90 mmHg and 1+ proteinuria plus 1 of: headache, clonus, visual disturbance, epigastric pain, oliguria, pulmonary oedema, raised liver enzymes, haemolysis, oligohydramnios, IUGR.
Interventions	MgSO4: according to local protocol. Either 4 g IV then 1 g/hr, or 6 g IV then 2 g/hr. Nimodipine: 60 mg 4 hourly, orally. Both regimens continued either for 24 hours total, or until 24 hours after delivery. Serum monitoring not required.
Outcomes	Woman: eclampsia, stroke, coagulopathy, respiratory problems, cardiac failure, antihypertensive drugs, side effects, abruption, caesarean section, PPH. Baby: RDS, hypotonia, intubation, hypotension.
Notes	Recruitment at 14 hospitals in 8 countries. Data for stillbirths and neonatal deaths not reported.
Risk of bias
Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Unclear risk	Randomisation stratified by centre, blocks of 6.
Allocation concealment?	Unclear risk	Sealed opaque envelopes.
Blinding? All outcomes	High risk	Unblinded trial, but primary outcome was described as "binary, objective, and not subject to measurement bias".
Incomplete outcome data addressed? All outcomes	Unclear risk	Recruitment 1995‐2000. 100 women (6%) excluded from analysis: 99 did not get allocated treatment, 1 withdrawn. Recruitment stopped early following interim analysis.